| __timestamp | BioCryst Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 7751000 |
| Thursday, January 1, 2015 | 13047000 | 10251000 |
| Friday, January 1, 2016 | 11253000 | 9575000 |
| Sunday, January 1, 2017 | 13933000 | 10912000 |
| Monday, January 1, 2018 | 29514000 | 11049000 |
| Tuesday, January 1, 2019 | 37121000 | 11646000 |
| Wednesday, January 1, 2020 | 67929000 | 13265000 |
| Friday, January 1, 2021 | 118818000 | 25805000 |
| Saturday, January 1, 2022 | 159371000 | 35182000 |
| Sunday, January 1, 2023 | 213894000 | 94999000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, BioCryst Pharmaceuticals and Viridian Therapeutics have shown contrasting trends in their SG&A expenses. From 2014 to 2023, BioCryst's SG&A costs surged by nearly 2,800%, peaking in 2023. In contrast, Viridian's expenses increased by approximately 1,200% over the same period.
BioCryst's expenses consistently outpaced Viridian's, with a notable spike in 2021, where their costs were over four times higher. This trend suggests BioCryst's aggressive investment in administrative functions, possibly reflecting strategic expansions or increased operational activities. Meanwhile, Viridian's more conservative growth in SG&A expenses might indicate a focus on cost efficiency. Understanding these dynamics offers valuable insights into each company's strategic priorities and financial health.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.